We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Human Blood Cell Disorders Tissue Bank

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00902447
Recruitment Status : Recruiting
First Posted : May 15, 2009
Last Update Posted : December 15, 2017
Sponsor:
Information provided by (Responsible Party):
Nicholas Chiorazzi, Northwell Health

Brief Summary:
The Human Blood Cell Disorder Tissue Bank will provide a convenient, comprehensive source of tissue containing populations of human blood cells from patients with various types of lymphoid, myeloid, and erythroid proliferative diseases as well as other associated conditions. The tissue bank will continue to be an invaluable asset for understanding of the biology of multiple blood cell disorders involving several cell types as well as the physiology of normal cellular counterparts affected in these disorders. Internal and external investigators will be able to utilize this tissue to test hypotheses relating to the immunologic, virologic, genetic, and molecular properties of these abnormal cells as well as normal cells from normal unaffected family members or normal aged matched subjects to provide better comparisons.

Condition or disease
Human Blood Cell Disorders Lymphoid, Myeloid and Erythroid Proliferative Disease

Study Type : Observational
Estimated Enrollment : 10000 participants
Observational Model: Case-Control
Time Perspective: Cross-Sectional
Official Title: Human Blood Cell Disorders Tissue Bank
Study Start Date : April 2009
Estimated Primary Completion Date : January 2019
Estimated Study Completion Date : January 2019

Group/Cohort
Human Blood Cell Disorders
Human Blood Cell Disorders Tissue Bank



Primary Outcome Measures :
  1. Accumulate tissue from patients with various blood disorders, including but not restricted to lymphoproliferative, myeloproliferative, and erythroproliferative conditions. [ Time Frame: Indefinite ]

Secondary Outcome Measures :
  1. Develop a database of at least 10,000 subjects who have donated samples for research as well as DNA banking, and who are willing to be contacted again for consideration of additional studies in the future. [ Time Frame: Indefinite ]

Biospecimen Retention:   Samples With DNA
cells, tissue, serum, saliva, etc


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 100 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Community sample
Criteria

Inclusion Criteria:

  • Participants or participant's Legally Authorized Representatives (LAR) must be able to understand and render voluntary, written informed consent.
  • Patients must be able to contribute the required amount of blood and/or tissue without compromising their well-being or care.
  • Participants must be willing to be contacted again for consideration of additional studies in the future, such as a blood draw or another action (e.g., bone marrow aspiration and/or biopsy) that would be done as part of their standard of care.

Exclusion Criteria:

  • Patients who are known to be anemic, with hemoglobin <8.0g/dl.
  • Patients who are known to be infected with HIV.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00902447


Contacts
Contact: Yasmine Kieso, MSCR ykieso@nshs.edu

Locations
United States, New York
The Feinstein Institute for Medical Research Recruiting
Manhasset, New York, United States, 11030
Contact: Yasmine Kieso, MSCR       ykieso@nshs.edu   
Principal Investigator: Nicholas Chiorazzi, M.D.         
Sponsors and Collaborators
Northwell Health
Investigators
Principal Investigator: Nicholas Chiorazzi, M.D. The Feinstein Institute for Medical Research

Responsible Party: Nicholas Chiorazzi, Investigator, The Feinstein Institute for Medical Research, Northwell Health
ClinicalTrials.gov Identifier: NCT00902447     History of Changes
Other Study ID Numbers: 08-202
First Posted: May 15, 2009    Key Record Dates
Last Update Posted: December 15, 2017
Last Verified: December 2017

Keywords provided by Nicholas Chiorazzi, Northwell Health:
Human Blood Cell Disorders
lymphoid, myeloid and erythroid proliferative disease

Additional relevant MeSH terms:
Disease
Pathologic Processes